Sequana Medical NV (EBR:SEQUA)

Market Cap	36.00M -53.7%
Revenue (ttm)	n/a -85.2%
Net Income	-51.85M
EPS	-1.11
Shares Out	71.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	339,648
Average Volume	228,764
Open	0.4980
Previous Close	0.4785
Day's Range	0.4815 - 0.5260
52-Week Range	0.4630 - 1.7740
Beta	-0.67
RSI	41.94
Earnings Date	Mar 27, 2026

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 48
• Stock Exchange: Euronext Brussels
• Ticker Symbol: SEQUA

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.